Invivyd, Inc. (NASDAQ:IVVD) Stock Has Consensus Target Price of $10.00

Invivyd, Inc. (NASDAQ:IVVD) has been assigned an average rating of “Hold” from the six analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $10.00.

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Invivyd in a report on Thursday, August 27th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research note on Tuesday, September 29th. Weiss Ratings raised shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research report on Monday, September 14th.

Invivyd Stock Down 7.5%

IVVD traded down $0.05 during trading hours on Friday, hitting $0.62. 3,450,516 shares of the company’s stock were exchanged, compared to its average volume of 7,816,278. The stock has a market cap of $182.34 million, a price-to-earnings ratio of -1.87 and a beta of 0.95. Invivyd has a 1-year low of $0.53 and a 1-year high of $3.07. The stock’s 50-day moving average is $0.82 and its two-hundred day moving average is $0.99.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. On average, equities research analysts anticipate that Invivyd will post -0.51 EPS for the current year.

Insider Buying and Selling

In other Invivyd news, insider Jill Andersen sold 37,256 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $0.72, for a total transaction of $26,824.32. Following the completion of the transaction, the insider directly owned 314,480 shares in the company, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 228,024 shares of company stock valued at $176,540. 12.25% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jupiter Topco LLC acquired a new stake in Invivyd during the 2nd quarter worth approximately $30,048,000. Janus Henderson Group PLC increased its position in Invivyd by 1.7% in the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock valued at $42,857,000 after acquiring an additional 551,188 shares during the period. BlackRock Inc. bought a new position in shares of Invivyd during the second quarter valued at $14,076,000. ADAR1 Capital Management LLC bought a new position in shares of Invivyd during the second quarter valued at $3,322,000. Finally, Eversept Partners LP raised its stake in shares of Invivyd by 6.4% during the first quarter. Eversept Partners LP now owns 2,276,349 shares of the company’s stock valued at $2,959,000 after acquiring an additional 136,219 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change.

Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S.